Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10
- 1 September 2006
- journal article
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 66 (1), 25-30
- https://doi.org/10.1016/j.ijrobp.2006.03.056
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Apoptosis in prostate cancer: Bax correlation with stageInternational Journal of Urology, 2005
- Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the diseaseProstate Cancer and Prostatic Diseases, 2005
- Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated With RadiotherapyClinical Cancer Research, 2004
- Molecular markers of outcome after radiotherapy in patients with prostate carcinomaCancer, 2003
- APOPTOSIS AND BCL-2 EXPRESSION IN PROSTATE CANCER:Journal of Urology, 2001
- BCL-2 AND P53 EXPRESSION IN CLINICALLY LOCALIZED PROSTATE CANCER PREDICTS RESPONSE TO EXTERNAL BEAM RADIOTHERAPYJournal of Urology, 1999
- LOCALLY RECURRENT PROSTATE TUMORS FOLLOWING EITHER RADIATION THERAPY OR RADICAL PROSTATECTOMY HAVE CHANGES IN KI-67 LABELING INDEX, P53 AND BCL-2 IMMUNOREACTIVITYJournal of Urology, 1998
- Immunohistochemical analysis of Ki‐67 antigen and Bcl‐2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapyBritish Journal of Urology, 1998
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958